218 related articles for article (PubMed ID: 33476303)
1. A genome-wide CRISPR/Cas9 screen in acute myeloid leukemia cells identifies regulators of TAK-243 sensitivity.
Barghout SH; Aman A; Nouri K; Blatman Z; Arevalo K; Thomas GE; MacLean N; Hurren R; Ketela T; Saini M; Abohawya M; Kiyota T; Al-Awar R; Schimmer AD
JCI Insight; 2021 Mar; 6(5):. PubMed ID: 33476303
[TBL] [Abstract][Full Text] [Related]
2. SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243.
Murai Y; Jo U; Murai J; Jenkins LM; Huang SN; Chakka S; Chen L; Cheng K; Fukuda S; Takebe N; Pommier Y
Cancer Res; 2021 Jun; 81(11):3067-3078. PubMed ID: 33863777
[TBL] [Abstract][Full Text] [Related]
3. Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity.
Mishra J; Simonsen R; Kumar N
J Biol Chem; 2019 Nov; 294(48):18337-18348. PubMed ID: 31653704
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
Grundy M; Seedhouse C; Russell NH; Pallis M
BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia.
Barghout SH; Patel PS; Wang X; Xu GW; Kavanagh S; Halgas O; Zarabi SF; Gronda M; Hurren R; Jeyaraju DV; MacLean N; Brennan S; Hyer ML; Berger A; Traore T; Milhollen M; Smith AC; Minden MD; Pai EF; Hakem R; Schimmer AD
Leukemia; 2019 Jan; 33(1):37-51. PubMed ID: 29884901
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxicity of cucurbitacin E from Citrullus colocynthis against multidrug-resistant cancer cells.
Saeed MEM; Boulos JC; Elhaboub G; Rigano D; Saab A; Loizzo MR; Hassan LEA; Sugimoto Y; Piacente S; Tundis R; Yagi S; Khalid H; Efferth T
Phytomedicine; 2019 Sep; 62():152945. PubMed ID: 31132750
[TBL] [Abstract][Full Text] [Related]
7. Expanding the Efflux In Vitro Assay Toolbox: A CRISPR-Cas9 Edited MDCK Cell Line with Human BCRP and Completely Lacking Canine MDR1.
Wegler C; Gazit M; Issa K; Subramaniam S; Artursson P; Karlgren M
J Pharm Sci; 2021 Jan; 110(1):388-396. PubMed ID: 33007277
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.
Wu CP; Sim HM; Huang YH; Liu YC; Hsiao SH; Cheng HW; Li YQ; Ambudkar SV; Hsu SC
Biochem Pharmacol; 2013 Feb; 85(3):325-34. PubMed ID: 23153455
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation.
Jaramillo AC; Cloos J; Lemos C; Stam RW; Kaspers GJL; Jansen G; Peters GJ
Leuk Res; 2019 Apr; 79():45-51. PubMed ID: 30849662
[TBL] [Abstract][Full Text] [Related]
11. ABCB1 limits the cytotoxic activity of TAK-243, an inhibitor of the ubiquitin-activating enzyme UBA1.
Wu Z; Yang Y; Lei Z; Narayanan S; Wang J; Teng Q; Murakami M; Ambudkar SV; Ping F; Chen Z
Front Biosci (Landmark Ed); 2022 Jan; 27(1):5. PubMed ID: 35090310
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of ABCG2 confers resistance to pevonedistat, an NAE inhibitor.
Wei LY; Wu ZX; Yang Y; Zhao M; Ma XY; Li JS; Yang DH; Chen ZS; Fan YF
Exp Cell Res; 2020 Mar; 388(2):111858. PubMed ID: 31972220
[TBL] [Abstract][Full Text] [Related]
13. Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells.
Chen YJ; Huang WC; Wei YL; Hsu SC; Yuan P; Lin HY; Wistuba II; Lee JJ; Yen CJ; Su WC; Chang KY; Chang WC; Chou TC; Chou CK; Tsai CH; Hung MC
PLoS One; 2011; 6(6):e21428. PubMed ID: 21731744
[TBL] [Abstract][Full Text] [Related]
14. FLT3-ITD and MLL-PTD influence the expression of MDR-1, MRP-1, and BCRP mRNA but not LRP mRNA assessed with RQ-PCR method in adult acute myeloid leukemia.
Nasilowska-Adamska B; Solarska I; Paluszewska M; Malinowska I; Jedrzejczak WW; Warzocha K
Ann Hematol; 2014 Apr; 93(4):577-93. PubMed ID: 24030729
[TBL] [Abstract][Full Text] [Related]
15. Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines.
Kalalinia F; Elahian F; Behravan J
J Cancer Res Clin Oncol; 2011 Feb; 137(2):321-30. PubMed ID: 20422426
[TBL] [Abstract][Full Text] [Related]
16. The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP.
Ambjørner SEB; Wiese M; Köhler SC; Svindt J; Lund XL; Gajhede M; Saaby L; Brodin B; Rump S; Weigt H; Brünner N; Stenvang J
Cells; 2020 Mar; 9(3):. PubMed ID: 32143347
[TBL] [Abstract][Full Text] [Related]
17. Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype.
Singh A; Wu H; Zhang P; Happel C; Ma J; Biswal S
Mol Cancer Ther; 2010 Aug; 9(8):2365-76. PubMed ID: 20682644
[TBL] [Abstract][Full Text] [Related]
18. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells.
Hirayama C; Watanabe H; Nakashima R; Nanbu T; Hamada A; Kuniyasu A; Nakayama H; Kawaguchi T; Saito H
Pharm Res; 2008 Apr; 25(4):827-35. PubMed ID: 17934801
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
Yanase K; Tsukahara S; Asada S; Ishikawa E; Imai Y; Sugimoto Y
Mol Cancer Ther; 2004 Sep; 3(9):1119-25. PubMed ID: 15367706
[TBL] [Abstract][Full Text] [Related]
20. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
